Double-Blind Trial Assessing the Efficacy of Intravesical Therapy in Non– Muscle Invasive Bladder Cancer. A pathological guided perspective

Zeeshan Shaukat, Khawar Ali, Muhammad Haroon Ghous, Muhammad Nadeem Shafique, Mukhtiar Ahmed, Mehveen Iqbal, Muhammad Ali Sumbal

Double-Blind Trial Assessing the Efficacy of Intravesical Therapy in Non– Muscle Invasive Bladder Cancer. A pathological guided perspective

Authors

Zeeshan Shaukat, Khawar Ali, Muhammad Haroon Ghous, Muhammad Nadeem Shafique, Mukhtiar Ahmed, Mehveen Iqbal, Muhammad Ali Sumbal

Keywords:

Non–muscle invasive bladder cancer, Intravesical therapy, Pathological guidance

Abstract

This randomized, double-blind, placebo-controlled trial aimed to evaluate the efficacy of intravesical therapy in patients with non–muscle invasive bladder cancer (NMIBC), utilizing pathological guidance for treatment stratification. A total of 200 patients diagnosed with
intermediate- to high-risk NMIBC were enrolled and randomized into two groups: one receiving intravesical therapy and the other a placebo.

References

Derré, L., et al. (2023). Intravesical Ty21a treatment of non-muscle invasive bladder cancer: A phase II clinical trial. Journal of Urology. (PubMed)

Porten, S. P., et al. (2015). Intravesical chemotherapy in non-muscle-invasive bladder cancer: A systematic review. Urology. (PubMed)

Downloads

Published

2025-10-28

How to Cite

Zeeshan Shaukat, Khawar Ali, Muhammad Haroon Ghous, Muhammad Nadeem Shafique, Mukhtiar Ahmed, Mehveen Iqbal, Muhammad Ali Sumbal. (2025). Double-Blind Trial Assessing the Efficacy of Intravesical Therapy in Non– Muscle Invasive Bladder Cancer. A pathological guided perspective. International Journal of Pharmacy Research & Technology (IJPRT), 15(2), 2908–2914. Retrieved from https://www.ijprt.org/index.php/pub/article/view/1132